Based on the ProKidney Corp. stock forecast from 3 analysts, the average analyst target price for ProKidney Corp. is USD 4.75 over the next 12 months. ProKidney Corp.’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of ProKidney Corp. is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, ProKidney Corp.’s stock price was USD 1.65. ProKidney Corp.’s stock price has changed by -20.29% over the past week, -16.24% over the past month and -6.25% over the last year.
No recent analyst target price found for ProKidney Corp.
No recent average analyst rating found for ProKidney Corp.
Company Overview ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina. Read Less
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell...Read More
Frequently Asked Questions About ProKidney Corp. (PROK) Stock
Based on ratings from 3 analysts ProKidney Corp.'s stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on PROK's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for PROK is USD 4.75 over the next 12 months. The maximum analyst target price is USD 6 while the minimum anlayst target price is USD 3.
Unfortunately we do not have enough data on PROK's stock to indicate if its overvalued.
The last closing price of PROK's stock was USD 1.65.
The most recent market capitalization for PROK is USD 1.81B.
Based on targets from 3 analysts, the average taret price for PROK is projected at USD 4.75 over the next 12 months.
This means that PROK's stock price may go up by +187.88% over the next 12 months.
We can't find any ETFs which contains ProKidney Corp.'s stock.
As per our most recent records ProKidney Corp. has 163 Employees.
ProKidney Corp.'s registered address is 2000 Frontis Plaza Blvd., Winston-Salem, NC, United States, 27103.
You can get more information about it from ProKidney Corp.'s website at https://www.prokidney.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About ProKidney Corp. (PROK) Stock
Based on ratings from 3 analysts ProKidney Corp.'s stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on PROK's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for PROK is USD 4.75 over the next 12 months. The maximum analyst target price is USD 6 while the minimum anlayst target price is USD 3.
Unfortunately we do not have enough data on PROK's stock to indicate if its overvalued.
The last closing price of PROK's stock was USD 1.65.
The most recent market capitalization for PROK is USD 1.81B.
Based on targets from 3 analysts, the average taret price for PROK is projected at USD 4.75 over the next 12 months.
This means that PROK's stock price may go up by +187.88% over the next 12 months.
We can't find any ETFs which contains ProKidney Corp.'s stock.
As per our most recent records ProKidney Corp. has 163 Employees.
ProKidney Corp.'s registered address is 2000 Frontis Plaza Blvd., Winston-Salem, NC, United States, 27103.
You can get more information about it from ProKidney Corp.'s website at https://www.prokidney.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PROK !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
